In conclusion, we demonstrated that trabectedin modulates the secretome and promotes cell death in senescent tumor cells, and identified NF-κB as a critical mediator of the drug's effects, suggesting the possibility to pharmacologically modulate the SASP and NF-κB in premature senescent tumor cells. Here, NFKB1 is linked to neoplasm.